175 related articles for article (PubMed ID: 14642608)
1. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.
Fiorucci S; Antonelli E; Brancaleone V; Sanpaolo L; Orlandi S; Distrutti E; Acuto G; Clerici C; Baldoni M; Del Soldato P; Morelli A
J Hepatol; 2003 Dec; 39(6):932-9. PubMed ID: 14642608
[TBL] [Abstract][Full Text] [Related]
2. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
Loureiro-Silva MR; Cadelina GW; Iwakiri Y; Groszmann RJ
J Hepatol; 2003 Dec; 39(6):940-6. PubMed ID: 14642609
[TBL] [Abstract][Full Text] [Related]
3. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Fiorucci S; Antonelli E; Tocchetti P; Morelli A
Cardiovasc Drug Rev; 2004; 22(2):135-46. PubMed ID: 15179450
[TBL] [Abstract][Full Text] [Related]
4. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
5. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
[TBL] [Abstract][Full Text] [Related]
6. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.
Fiorucci S; Antonelli E; Morelli O; Mencarelli A; Casini A; Mello T; Palazzetti B; Tallet D; del Soldato P; Morelli A
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8897-902. PubMed ID: 11447266
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver.
Fiorucci S; Antonelli E; Morelli A
Dig Liver Dis; 2003 May; 35 Suppl 2():S61-9. PubMed ID: 12846445
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
[TBL] [Abstract][Full Text] [Related]
9. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats.
Van de Casteele M; Hösli M; Sägesser H; Reichen J
J Hepatol; 1999 Aug; 31(2):300-5. PubMed ID: 10453944
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
[TBL] [Abstract][Full Text] [Related]
11. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-releasing aspirin inhibits vasoconstriction in perfused tail artery of normotensive and spontaneously hypertensive rats.
Rossoni G; Manfredi B; Del Soldato P; Polvani G; Berti F
Eur J Pharmacol; 2003 Sep; 477(1):59-68. PubMed ID: 14512099
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats.
Moal F; Veal N; Vuillemin E; Barrière E; Wang J; Fizanne L; Oberti F; Douay O; Gallois Y; Bonnefont-Rousselot D; Rousselet MC; Calès P
World J Gastroenterol; 2006 Nov; 12(41):6639-45. PubMed ID: 17075977
[TBL] [Abstract][Full Text] [Related]
16. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.
Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096
[TBL] [Abstract][Full Text] [Related]
17. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension.
Kamath PS; Tyce GM; Miller VM; Edwards BS; Rorie DK
Hepatology; 1999 Aug; 30(2):401-7. PubMed ID: 10421647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
